Qnovia Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $14.2M

  • Investors
  • 10

Qnovia General Information

Description

Developer of a drug delivery platform designed to advance pharmaceutical research and treatments aimed at saving lives. The company's platform offers an inhalation-based technology that addresses many of the limitations of traditional pharmaceutical drug delivery systems to improve patient outcomes that optimize human factors and tackle critical medical challenges, enabling patients to get a variety of new inhaled therapies and improve health.

Contact Information

Website
www.qnovia.com
Formerly Known As
Respira Technologies
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2920 West Broad Street
  • Suite 243
  • Richmond, VA 23230
  • United States
+1 (973)
Primary Industry
Therapeutic Devices
Other Industries
Drug Delivery
Vertical(s)
Corporate Office
  • 2920 West Broad Street
  • Suite 243
  • Richmond, VA 23230
  • United States
+1 (973)

Qnovia Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Qnovia Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series B) 10-Dec-2024 $14.2M Completed Generating Revenue
2. Later Stage VC (Series A) 07-Jun-2023 Completed Generating Revenue
1. Seed Round 13-Jan-2020 $2.25M $2.25M Completed Generating Revenue
To view Qnovia’s complete valuation and funding history, request access »

Qnovia Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A-6
A-5 Preferred
A-4 Preferred
A-3 Preferred
A-2 Preferred 419,251 $0.000100 $16.42 $16.42 1x $16.42 3.24%
A-1 Preferred 1,053,741 $0.000100 $19.32 $19.32 1x $19.32 8.14%
To view Qnovia’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Qnovia Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a drug delivery platform designed to advance pharmaceutical research and treatments aimed at saving lives.
Therapeutic Devices
Richmond, VA
8 As of 2023

Palo Alto, CA
 

San Mateo, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Qnovia Competitors (5)

One of Qnovia’s 5 competitors is Respira Therapeutics, a Venture Capital-Backed company based in Palo Alto, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Respira Therapeutics Venture Capital-Backed Palo Alto, CA
Cala Health Venture Capital-Backed San Mateo, CA
Verge Labs Venture Capital-Backed San Francisco, CA
Cycle Pharmaceuticals Corporation Cambridge, United Kingdom
Sarepta Therapeutics Formerly VC-backed Cambridge, MA
You’re viewing 5 of 5 competitors. Get the full list »

Qnovia Patents

Qnovia Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4510873-A1 Electronic devices for aerosolizing and inhaling liquid Pending 22-Apr-2022
EP-4510873-A4 Electronic devices for aerosolizing and inhaling liquid Pending 22-Apr-2022
US-20230337735-A1 Electronic devices for aerosolizing and inhaling liquid Active 22-Apr-2022
US-20230389605-A1 Electronic devices for aerosolizing and inhaling liquid Active 22-Apr-2022
US-20240407432-A1 Electronic devices for aerosolizing and inhaling liquid Active 22-Apr-2022 A24F40/485
To view Qnovia’s complete patent history, request access »

Qnovia Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Qnovia Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Timeless Ventures Venture Capital Minority
Gaingels Venture Capital Minority
Third Lake Capital Family Office Minority
Vice Ventures Venture Capital Minority
Blue Ledge Capital Venture Capital Minority
You’re viewing 5 of 10 investors. Get the full list »

Qnovia FAQs

  • When was Qnovia founded?

    Qnovia was founded in 2018.

  • Where is Qnovia headquartered?

    Qnovia is headquartered in Richmond, VA.

  • What is the size of Qnovia?

    Qnovia has 8 total employees.

  • What industry is Qnovia in?

    Qnovia’s primary industry is Therapeutic Devices.

  • Is Qnovia a private or public company?

    Qnovia is a Private company.

  • What is the current valuation of Qnovia?

    The current valuation of Qnovia is .

  • What is Qnovia’s current revenue?

    The current revenue for Qnovia is .

  • How much funding has Qnovia raised over time?

    Qnovia has raised $43.5M.

  • Who are Qnovia’s investors?

    Timeless Ventures, Gaingels, Third Lake Capital, Vice Ventures, and Blue Ledge Capital are 5 of 10 investors who have invested in Qnovia.

  • Who are Qnovia’s competitors?

    Respira Therapeutics, Cala Health, Verge Labs, Cycle Pharmaceuticals, and Sarepta Therapeutics are competitors of Qnovia.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process